Reliance Institute of Life Sciences

FDAnews Announces Quality, Compliance and Validation in the Digital Transformation Era Webinar Sponsored by Axendia & Tulip March 8, 2022

Retrieved on: 
Wednesday, March 2, 2022
Digital, Digital transformation, Reliance Institute of Life Sciences, Doctor of Philosophy, COVID-19, Compliance, CSV, FDA, Culture, Cryptocurrency

With the productivity gains one will will make coupled with the digital acceleration brought about by COVID-19 changing course is a business imperative.

Key Points: 
  • With the productivity gains one will will make coupled with the digital acceleration brought about by COVID-19 changing course is a business imperative.
  • It will take the dread out of the transformation and empower one to modernize the systems and culture with new approaches to quality, compliance and validation.
  • Add to this the formation and structure of the FDA's new Office of Digital Transformation; it signals the serious stance the agency is taking on digital transformation.
  • With the regulators undergoing their own digital transformations and incentivizing life science companies to do the same it's time to move forward.

Global Research Antibodies Market Drivers 2021-2028 Include Rise In The Availability Of Technologically Advanced Products and a Rise In Proteomics And Genomics Research - ResearchAndMarkets.com

Retrieved on: 
Friday, December 3, 2021
Biotechnology, Health, Science, Stem Cells, Research, Government, Genomics, Adoption, ILS, Industry, Merck, Polyclonal antibodies, Proteomics, AbCellera, CAGR, Diagnosis, Antigen, USD, Workflow, Application, D, List of life sciences, Laboratory, Institute, COVID-19, GSK, Map, Neutralizing antibody, Technology, Research, Neuroscience, Biotechnology, Antibody, Sanofi, Reliance Institute of Life Sciences, Drug development, Vaccine, Fine chemical

The global research antibodies market size is expected to reach USD 5.9 billion by 2028.

Key Points: 
  • The global research antibodies market size is expected to reach USD 5.9 billion by 2028.
  • The market is expected to expand at a CAGR of 6.4% from 2021 to 2028.
  • Major market drivers include a rise in R&D initiatives undertaken by biopharmaceutical and biotechnology companies and government bodies, an increase in neurobiology and stem cell research, availability of technologically advanced products, and strategic collaborations among various key players.
  • Additionally, a rise in funds invested by pharmaceutical and biotechnology companies to enhance proteomics and genomics research is expected to boost market growth.

Moderna and the Institute for Life Changing Medicines Announce a New Collaboration to Develop an mRNA Therapeutic for Ultra-Rare Disease, Crigler-Najjar Syndrome Type 1

Retrieved on: 
Tuesday, September 7, 2021
Research, Infectious Diseases, Genetics, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, mRNA-3351, The Institute for Life Changing Medicines, Moderna, MRNA-3351, THE INSTITUTE FOR LIFE CHANGING MEDICINES, MODERNA

The goal of the collaboration is to make an mRNA therapy for the treatment of CN-1 available at no cost to patients.

Key Points: 
  • The goal of the collaboration is to make an mRNA therapy for the treatment of CN-1 available at no cost to patients.
  • At Moderna, we believe that mRNA therapies have the potential to profoundly impact rare disease patients and their families.
  • In this innovative partnership, the Institute for Life Changing Medicines will not pay Moderna an upfront fee or any downstream payments.
  • The Institute for Life Changing Medicines believes that a healthy life is a basic human right.